Both biodistribution studies in U87MG tumor-bearing murine models and small animal PET studies have shown increased immuno-PET radiotracer retention in tumors over time, and the accumulation of radiotracers was a specific marker of FAP expression, indicating that FAP might be a potential imaging biomarker for GBM diagnosis [11]. This evidence concerns the gene FAP and glioblastoma.